Co-cultivation is a powerful approach to produce a robust functionally designed synthetic consortium as a live biotherapeutic product (LBP)

ABSTRACT The success of fecal microbiota transplants (FMT) has provided the necessary proof-of-concept for microbiome therapeutics. Yet, feces-based therapies have many associated risks and uncertainties, and hence defined microbial consortia that modify the microbiome in a targeted manner have emerged as a promising safer alternative to FMT. The development of such live biotherapeutic products has important challenges, including the selection of appropriate strains and the controlled production of the consortia at scale. Here, we report on an ecology- and biotechnology-based approach to microbial consortium construction that overcomes these issues. We selected nine strains that form a consortium to emulate the central metabolic pathways of carbohydrate fermentation in the healthy human gut microbiota. Continuous co-culturing of the bacteria produces a stable and reproducible consortium whose growth and metabolic activity are distinct from an equivalent mix of individually cultured strains. Further, we showed that our function-based consortium is as effective as FMT in counteracting dysbiosis in a dextran sodium sulfate mouse model of acute colitis, while an equivalent mix of strains failed to match FMT. Finally, we showed robustness and general applicability of our approach by designing and producing additional stable consortia of controlled composition. We propose that combining a bottom-up functional design with continuous co-cultivation is a powerful strategy to produce robust functionally designed synthetic consortia for therapeutic use.

[1]  V. Bucci,et al.  Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. , 2022, Cell host & microbe.

[2]  Ophelia S. Venturelli,et al.  Model-guided design of the diversity of a synthetic human gut community , 2022, bioRxiv.

[3]  Jean C. C. Vila,et al.  Diversity begets diversity under microbial niche construction , 2022, bioRxiv.

[4]  N. Neff,et al.  In vivo augmentation of a complex gut bacterial community , 2021, bioRxiv.

[5]  R. Sartor,et al.  Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis , 2021, Nature Communications.

[6]  Victòria Pascal Andreu,et al.  A systematic analysis of metabolic pathways in the human gut microbiota , 2021, bioRxiv.

[7]  M. Wagner,et al.  Rational design of a microbial consortium of mucosal sugar utilizers reduces Clostridiodes difficile colonization , 2020, Nature Communications.

[8]  Otto X. Cordero,et al.  Trophic Interactions and the Drivers of Microbial Community Assembly , 2020, Current Biology.

[9]  J. Parkhill,et al.  Pivotal Roles for pH, Lactate, and Lactate-Utilizing Bacteria in the Stability of a Human Colonic Microbial Ecosystem , 2020, mSystems.

[10]  H. Bono,et al.  Full-length 16S rRNA gene amplicon analysis of human gut microbiota using MinION™ nanopore sequencing confers species-level resolution , 2020, BMC Microbiology.

[11]  Donovan H. Parks,et al.  A complete domain-to-species taxonomy for Bacteria and Archaea , 2020, Nature Biotechnology.

[12]  B. Stecher,et al.  A standardized gnotobiotic mouse model harboring a minimal 15-member mouse gut microbiota recapitulates SOPF/SPF phenotypes , 2019, Nature Communications.

[13]  J. Vendrell,et al.  Gut microbiota-derived succinate: Friend or foe in human metabolic diseases? , 2019, Reviews in Endocrine and Metabolic Disorders.

[14]  E. Allen-Vercoe,et al.  Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health , 2019, Microbiome.

[15]  K. Coyte,et al.  Understanding Competition and Cooperation within the Mammalian Gut Microbiome , 2019, Current Biology.

[16]  Katherine S. Pollard,et al.  New insights from uncultivated genomes of the global human gut microbiome , 2019, Nature.

[17]  Chao-hai Wei,et al.  Application of metabolic division of labor in simultaneous removal of nitrogen and thiocyanate from wastewater. , 2019, Water research.

[18]  Yinjie J. Tang,et al.  Engineering microbial consortia by division of labor , 2019, Microbial Cell Factories.

[19]  J. V. van Limbergen,et al.  The Role of Succinate in the Regulation of Intestinal Inflammation , 2018, Nutrients.

[20]  N. Roy,et al.  Hydrogen cross-feeders of the human gastrointestinal tract , 2018, Gut microbes.

[21]  Eric A. Franzosa,et al.  Gut microbiome structure and metabolic activity in inflammatory bowel disease , 2018, Nature Microbiology.

[22]  Michael A Fischbach,et al.  Microbiome: Focus on Causation and Mechanism , 2018, Cell.

[23]  Y. Yang,et al.  Fecal microbiota transplantation: Current status and challenges in China , 2018, JGH open : an open access journal of gastroenterology and hepatology.

[24]  M. Hudson Human , 2018, Critical Theory and the Classical World.

[25]  Andreas Wagner,et al.  An enormous potential for niche construction through bacterial cross-feeding in a homogeneous environment , 2018, PLoS Comput. Biol..

[26]  Patrice D Cani Human gut microbiome: hopes, threats and promises , 2018, Gut.

[27]  D. Hadrich Microbiome Research Is Becoming the Key to Better Understanding Health and Nutrition , 2018, Front. Genet..

[28]  Michaeline B. N. Albright,et al.  Function and functional redundancy in microbial systems , 2018, Nature Ecology & Evolution.

[29]  C. Sander,et al.  Computer-guided design of optimal microbial consortia for immune system modulation , 2018, eLife.

[30]  P. Bork,et al.  The Human Gut Microbiome: From Association to Modulation , 2018, Cell.

[31]  Yu Lin,et al.  Assembly of long, error-prone reads using repeat graphs , 2018, Nature Biotechnology.

[32]  Yorick Janssens,et al.  Faecal microbiota transplantation: a regulatory hurdle? , 2017, BMC Gastroenterology.

[33]  C. Chassard,et al.  Lactate-utilizing community is associated with gut microbiota dysbiosis in colicky infants , 2017, Scientific Reports.

[34]  D. Or,et al.  Synthetic Microbial Ecology: Engineering Habitats for Modular Consortia , 2017, Front. Microbiol..

[35]  J. Overmann,et al.  Cultured microbes represent a substantial fraction of the human and mouse gut microbiota , 2017, Gut microbes.

[36]  C. Hill,et al.  Next-generation probiotics: the spectrum from probiotics to live biotherapeutics , 2017, Nature Microbiology.

[37]  A. Moss,et al.  Fecal Microbiota Transplantation: From Clostridium difficile to Inflammatory Bowel Disease. , 2017, Gastroenterology & hepatology.

[38]  M. Kamm,et al.  Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial , 2017, The Lancet.

[39]  Ryan R. Wick,et al.  Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads , 2016, bioRxiv.

[40]  Philipp C. Münch,et al.  Genome-guided design of a defined mouse microbiota that 1 confers colonization resistance against Salmonella enterica 2 serovar Typhimurium 3 , 2018 .

[41]  Bangmao Wang,et al.  Systematic Review: Adverse Events of Fecal Microbiota Transplantation , 2016, PloS one.

[42]  Qian Ma,et al.  Design, analysis and application of synthetic microbial consortia , 2016, Synthetic and systems biotechnology.

[43]  Paul J. McMurdie,et al.  DADA2: High resolution sample inference from Illumina amplicon data , 2016, Nature Methods.

[44]  M. Surette,et al.  Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. , 2015, Gastroenterology.

[45]  Guang-li Cao,et al.  Developing a mesophilic co-culture for direct conversion of cellulose to butanol in consolidated bioprocess , 2015, Biotechnology for Biofuels.

[46]  E. Zoetendal,et al.  Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. , 2015, World journal of gastroenterology.

[47]  V. Young,et al.  The gut microbiome in health and in disease , 2015, Current opinion in gastroenterology.

[48]  A. Gasbarrini,et al.  Fecal Microbiota Transplantation in Inflammatory Bowel Disease: Beyond the Excitement , 2014, Medicine.

[49]  Torsten Seemann,et al.  Prokka: rapid prokaryotic genome annotation , 2014, Bioinform..

[50]  Jenny Sauk,et al.  Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  Orkun S. Soyer,et al.  Synthetic microbial communities , 2014, Current opinion in microbiology.

[52]  James C Liao,et al.  Design and characterization of synthetic fungal-bacterial consortia for direct production of isobutanol from cellulosic biomass , 2013, Proceedings of the National Academy of Sciences.

[53]  Nico Boon,et al.  Routine bacterial analysis with automated flow cytometry. , 2013, Journal of microbiological methods.

[54]  C. Chassard,et al.  Carbohydrates and the human gut microbiota , 2013, Current opinion in clinical nutrition and metabolic care.

[55]  Bernard Henrissat,et al.  The abundance and variety of carbohydrate-active enzymes in the human gut microbiota , 2013, Nature Reviews Microbiology.

[56]  B. Olle,et al.  Medicines from microbiota , 2013, Nature Biotechnology.

[57]  Christophe Lacroix,et al.  Microbe-microbe interactions in mixed culture food fermentations. , 2013, Current opinion in biotechnology.

[58]  R. Knight,et al.  Diversity, stability and resilience of the human gut microbiota , 2012, Nature.

[59]  Katherine H. Huang,et al.  Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.

[60]  Helong Jiang,et al.  Mechanisms of enhanced cellulosic bioethanol fermentation by co-cultivation of Clostridium and Thermoanaerobacter spp. , 2011, Bioresource technology.

[61]  S. Ragsdale,et al.  Acetogenesis and the Wood-Ljungdahl pathway of CO(2) fixation. , 2008, Biochimica et biophysica acta.

[62]  H. Flint,et al.  Assessment of metabolic diversity within the intestinal microbiota from healthy humans using combined molecular and cultural approaches. , 2008, FEMS microbiology ecology.

[63]  Wenying Shou,et al.  Synthetic cooperation in engineered yeast populations , 2007, Proceedings of the National Academy of Sciences.

[64]  H. Flint,et al.  Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. , 2002, International journal of systematic and evolutionary microbiology.

[65]  H. Flint,et al.  Degradation and utilization of xylans by the rumen anaerobe Prevotella bryantii (formerly P. ruminicola subsp. brevis) B(1)4. , 1997, Anaerobe.

[66]  Falk Hildebrand,et al.  Enterotypes in the landscape of gut microbial community composition , 2017, Nature Microbiology.

[67]  Hans C. Bernstein,et al.  Gazing into the crystal ball : predicting the behavior of microbial consortia , 2016 .

[68]  H. Flint,et al.  ‘ Diet, gut microbiology and human health , 2015 .

[69]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[70]  Peer Bork,et al.  Enterotypes of the human gut microbiome , 2011, Nature.

[71]  G. Diekert,et al.  Metabolism of homoacetogens , 2004, Antonie van Leeuwenhoek.